TI
LRMR icon

Trexquant Investment’s Larimar Therapeutics LRMR Stock Holding History

Trexquant Investment’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-123,066
Closed -$476K – 1735
2024
Q4 		$476K Sell
123,066
-28,041
-19% -$185K 0.01% 1294
2024
Q3 		$990K Sell
151,107
-35,067
-19% -$282K 0.01% 1056
2024
Q2 		$1.35M Buy
186,174
+139,980
+303% +$1.07M 0.02% 895
2024
Q1 		$351K Buy
+46,194
New +$360K 0.01% 1249
2023
Q2 		– Sell
-34,603
Closed -$157K – 1637
2023
Q1 		$157K Buy
+34,603
New +$181K ﹤0.01% 1354
2019
Q1 		– Sell
-2,408
Closed -$143K – 1161
2018
Q4 		$143K Buy
+2,408
New +$238K 0.01% 961
2018
Q3 		– Sell
-953
Closed -$117K – 1088
2018
Q2 		$117K Buy
+953
New +$81K 0.01% 827

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Trexquant Investment's LRMR Position: Q1 2025 in Review

Trexquant Investment sold out of Larimar Therapeutics (LRMR) in Q1 2025, closing a stake of 123,066 shares — an estimated $476K sold.

Trexquant Investment first reported a position in LRMR in Q2 2018 and held it in 7 quarters. The position peaked at $1.35M in Q2 2024. 103 funds tracked by Wall St. Rank hold LRMR as of Q1 2025.

  • Trexquant Investment reported no remaining Larimar Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Trexquant Investment sold 123,066 Larimar Therapeutics shares in Q1 2025, an estimated $476K.
  • Trexquant Investment first reported a position in Larimar Therapeutics in Q2 2018 and held it in 7 quarters.
  • Trexquant Investment's Larimar Therapeutics position peaked at $1.35M in Q2 2024.
  • 103 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2025.

Based on Trexquant Investment's 13F filing for Q1 2025, filed 14 May 2025.